Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2025 17:05 ET | Source: Genmab A/S

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Media ReleaseCOPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S®) in patients with recurrent/advanced...
May 21, 2025 10:02 ET | Source: Genmab A/S

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies...
May 20, 2025 12:01 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase...
May 19, 2025 09:08 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...
May 14, 2025 10:15 ET | Source: Genmab A/S

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Media ReleaseCOPENHAGEN, Denmark; May 14, 2025 Data from 14 abstracts highlight the depth, breadth, and strength of Genmab’s comprehensive epcoritamab development program across multiple patient...
May 12, 2025 08:51 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...
May 08, 2025 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2024

May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for...
May 05, 2025 08:23 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 5, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...
May 01, 2025 20:14 ET | Source: Genmab A/S

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trialFull results from...
April 28, 2025 08:16 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...